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Abstract
Objective
To understand geographic variations in clinical retention, a central component of the HIV
care continuum and key to improving individual- and population-level HIV outcomes.
Design
We evaluated retention by US region in a retrospective observational study.
Methods
Adults receiving care from 2000–2010 in 12 clinical cohorts of the North American AIDS
Cohort Collaboration on Research and Design (NA-ACCORD) contributed data. Individuals
were assigned to Centers for Disease Control and Prevention (CDC)-defined regions by
residential data (10 cohorts) and clinic location as proxy (2 cohorts). Retention was2 pri-
mary HIV outpatient visits within a calendar year, >90 days apart. Trends and regional differ-
ences were analyzed using modified Poisson regression with clustering, adjusting for time
in care, age, sex, race/ethnicity, and HIV risk, and stratified by baseline CD4+ count.
Results
Among 78,993 adults with 444,212 person-years of follow-up, median time in care was 7
years (Interquartile Range: 4–9). Retention increased from 2000 to 2010: from 73% (5,000/
6,875) to 85% (7,189/8,462) in the Northeast, 75% (1,778/2,356) to 87% (1,630/1,880) in
the Midwest, 68% (8,451/12,417) to 80% (9,892/12,304) in the South, and 68% (5,147/
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7,520) to 72% (6,401/8,895) in the West. In adjusted analyses, retention improved over time
in all regions (p<0.01, trend), although the average percent retained lagged in the West and
South vs. the Northeast (p<0.01).
Conclusions
In our population, retention improved, though regional differences persisted even after
adjusting for demographic and HIV risk factors. These data demonstrate regional differ-
ences in the US which may affect patient care, despite national care recommendations.
Introduction
Mapping health outcomes and identifying geographic variations in care are useful tools in pub-
lic health, assisting decision-makers in identifying locales in greatest need of resources.[1–7]
The field of HIV epidemiology has been no exception, and analyses of geographic variation in
HIV incidence, extent, severity, and intervention effectiveness have yielded insights into the
changing nature and trajectory of the pandemic.[8–16] In the U.S., HIV prevalence, incidence,
disease progression, treatment, and mortality have been noted to differ across geographic
regions and individual states.[17–21]
Retention in care is associated with improved access to antiretroviral therapy (ART), greater
likelihood of virologic suppression, and less rapid HIV disease progression.[22–27] Similarly,
the same demographic, clinical, and socioeconomic factors (i.e., younger age, Black race, higher
CD4 count, and unstable housing status) have been repeatedly associated with suboptimal
retention in various contexts. However, these analyses have rarely focused on geographic het-
erogeneity as a potential source of clinical retention differences and have incorporated these
data by adjusting for clinic site in multi-site analyses or examining relatively small numbers of
jurisdictions.[28–39] Further, some of the studies in which these patterns of retention were dis-
cerned may have cohort-specific traits which could affect clinic attendance such as state Medic-
aid funding levels or local social stigmas (e.g., a history of intolerance toward sexual minorities)
that could limit their external generalizability to persons living with HIV/AIDS (PLWHA) in
the U.S. Nevertheless, recent major policy initiatives, including the National HIV/AIDS Strat-
egy (NHAS), have identified improving clinical retention, and targeting impediments to these
improvements, as goals central to improving outcomes across the HIV Care Continuum in the
U.S.[40–43]
Yet retention in care requires consistent and ongoing interaction with the healthcare system,
a process which may include various obstacles which differ geographically (due to demo-
graphic, economic, risk behavior, political, and cultural factors).[9,20,21,35,44] In consider-
ation of these issues, our aim was to describe the geography of clinical care experience over
time in order to provide evidence for evaluating benchmarks of national HIV policy goals and
to better understand factors that are pertinent to public health interventions designed to
improve retention in HIV care.[42] We therefore quantified the geographic heterogeneity of
retention between 2000 and 2010 within a large and geographically diverse HIV cohort that is
demographically similar to PLWHA in the U.S.[45]
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Methods
Population and study design
The North American AIDS Cohort Collaboration on Research and Design (NA-ACCORD)
represents the United States and Canada in the International epidemiologic Databases to Eval-
uate AIDS (IeDEA) project. The NA-ACCORD began collecting data from multi- and single-
site interval and clinical cohorts in 2006.[46] The Institute of Medicine of the National Acade-
mies (IOM) has promulgated the NA-ACCORD, due to its size and demographic similarity
with PLWHA in the U.S., as one of 12 data systems appropriate to assess quality of care goals,
such as improving clinical retention, in the NHAS and Affordable Care Act [24] Details of the
data collection and submission process for the NA-ACCORD have been published previously.
[47] Briefly, clinical, demographic, and geographic data from 25 cohorts are transmitted to a
centrally-administered Data Management Core annually where all contributed data are harmo-
nized. Data undergo quality control for completeness and accuracy, including measures to
reduce the probability that an individual was concurrently participating in more than one clini-
cal cohort. The activities of the NA-ACCORD and each of its participating cohorts have been
reviewed and approved by their respective local institutional review boards and by the Johns
Hopkins School of Medicine institutional review board. Written consent was either obtained
individually, or else waivers of individual consent were obtained through each site’s respective
local institutional review board. All data were de-identified prior to analysis.
Among clinical cohorts, only patients with 2 HIV primary care visits within 12 months
were enrolled into the NA-ACCORD, limiting the NA-ACCORD population to patients suc-
cessfully linked to and established as “in care” proximal to cohort entry.[24,26]
Adult participants who had 1 HIV primary care visit between January 2000 and Decem-
ber 2010 were included in this longitudinal, retrospective cohort study. Classic prospective
cohorts were excluded to allow an exclusive focus on patterns of patient clinical care in clinical
cohorts. Canadian cohorts were also excluded. The 12 included clinical cohorts were comprised
of patients from all 50 U.S. states, Washington, D.C., and Puerto Rico, 818 of 887 US 3-digit
ZIP Code Tabulation Areas (ZCTA), and 167 clinical sites located in areas of dense population
across the country.
Our nested study was reviewed by the Johns Hopkins Bloomberg School of Public Health
institutional review board, and it was deemed non-human-subject/non-research because it was
a secondary analysis of existing, anonymized/de-identified data.
Retention measures, factors associated with retention, and follow-up
The outcome for our analysis was clinical retention in care (“retention”), defined using the
IOM indicator: 2 HIV primary care visits within a calendar year, 90 days apart.[24] This
measure was used because it is the same as that adopted in the National HIV/AIDS Strategy.
We have previously evaluated the strong agreement of this indicator with DHHS indicators
and with laboratory proxies.[25,48] Only HIV primary care encounters were used to define
retention. Other outpatient encounter types, including subspecialty care, emergency depart-
ment, dental, mental health, nursing, nutrition, orientation, pharmacy, social work/case man-
ager, substance abuse, and other/unknown outpatient encounters, were not used for these
analyses. Inpatient visits and laboratory only visits were also excluded.
Participant age (<40, 40–49, 50–59, and60 years), sex, race/ethnicity (White, Black, His-
panic, or other/unknown), HIV acquisition risk factor (male sexual contact with men (MSM),
injection drug use [IDU], heterosexual contact, or other/unknown), receipt of ART for6
months in a year (3 antiretroviral drugs from2 classes, or a triple nucleoside/nucleotide
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reverse transcriptase inhibitor (NRTI) regimen containing abacavir or tenofovir), first CD4
+ cell count during each year of follow-up, last HIV-1 RNAmeasure during each year of fol-
low-up, and geographic location of residence (US Centers for Disease Control (CDC)-defined
region, state, and 3-digit ZCTA) were included in analyses of factors by which clinical retention
may have differed. The composition of regions by state is described below.
ART receipt and CD4+ cell count were used in secondary analyses as baseline covariates for
stratification indicating health status and access to care at cohort enrollment; HIV-1 RNA was
excluded from regression analyses due to its putative role as time-dependent confounder in the
longitudinal relationship between demographic and HIV risk characteristics and retention.
Geographic location of patient residence was collected at cohort entry and was not allowed to
vary over time due to limited availability of residential movement data over the study period.
Individual data were summarized into one observation per year between 2000 (at the earli-
est) and the final encounter prior to the end of 2010. The initial year of care was excluded if the
patient entered in the final quarter of a calendar year (and were thus ineligible to be “retained”
in their year of entry). Year of death during the study period was excluded from analyses due to
individuals not being uniformly “at risk” for successful retention in that year. Follow-up time
ranged between 1 and 11 person-years, and individuals contributed multiple outcomes while
under observation.
Additional geographic information
Location of patient residence by ZCTA was collected by individual clinical cohorts. Data con-
sistency checks were performed to ensure that ZCTA of residence corresponded correctly with
state of residence (as ZCTAs may be aggregated to the state-level along coterminous bound-
aries). State of residence was used to assign patients to geographic regions of the U.S. based on
CDC and US Census Bureau definitions. US CDC-defined regions were: Northeast: CT, ME,
MA, NH, NJ, NY, PA, RI, VT; Midwest: IL, IN, IA, KS, MI, MN, MO, NE, ND, OH, SD, WI;
South: AL, AR, DE, DC, FL, GA, KY, LA, MD, MS, NC, OK, SC, TN, TX, VA, WV; andWest:
AK, AZ, CA, CO, HI, ID, MT, NV, NM, OR, UT, WA, WY.[49] Demographic, geographic,
and economic characteristics of ZCTAs were derived from 2000 and 2010 US decennial census
estimates and assigned as follows: for years 2000–2003: from the 2000 census; for years 2008–
2010: from the 2010 census; and for years 2004–2007: mid-point estimates between census
years 2000 and 2010. Census-derived population-level variables included median age within
the ZCTA and proportions of the ZCTA that were of female sex, of Black race, residing in a
rural area, and living below the Federal poverty level. Rural areas and the poverty level were
defined according to US Census Bureau standards.[50] For ZCTA-level analyses, individual
characteristics from NA-ACCORD participants were aggregated to the ZCTA level as median
age in the sample, and the proportion of the sample that were of female sex, of Black race, and
that had IDU as an HIV risk factor within the ZCTA.
For participants from 2 clinical cohorts (N = 35,131) whose residential data was unavailable,
clinic location was used as a proxy for state of residence, but not for ZCTA; individuals from
these cohorts were included in descriptions and analyses of regional and state-level differences
in retention but not in analyses using ZCTA-level data.
Statistical models and methods
Regional differences in the percentage of patients clinically retained within strata of demo-
graphic and clinical characteristics were detected by χ2 test. Modified Poisson regression using
a Generalized Estimating Equation (GEE) was used to assess temporal trends and determine
the relative risks (RR) and 95% confidence intervals (CI) of retention based on demographic
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and geographic factors at the individual level.[51] An unstructured working correlation was
used for repeated outcomes within individuals in the GEE regression.[52,53] Time during the
study period (i.e., study year) was included in models as a restricted cubic spline with 3 knots
(at 2, 6, and 10 years) and as a categorical term for predictive margins.[54] All individual-level
models were also adjusted for total time contribution to the study (to account for possible
cohort effects) and for contributing cohort site (to account for potential clinical practice differ-
ences). All proportions at the ZCTA level were mean-centered to ease interpretation in logistic
regression modeling using GEE. In secondary analyses, the relationship between baseline CD4-
+ count and ART use with retention were assessed to explore regional differences in retention
trajectories by initial access to care and late diagnosis. Interaction terms for region-by-baseline
factors were included with the full Poisson regression model used in primary analyses at the
individual level. Missing baseline CD4+ counts were multiply imputed using a predictive mean
model regression including baseline age, sex, race/ethnicity, HIV risk factor, ART use, and
cohort site.[55]
Population-averaged effects are generally viewed as more germane to policy decisions, and
there is evidence that mixed effects approaches may induce bias in this context.[56,57] Thus,
the population-averaged model was employed here. ZCTA-level differences in proportions
retained were also explored using logistic regression with GEE, adjusting for aggregated indi-
vidual and ZCTA-level census characteristics.[58,59] Additional details of Poisson and logistic
regression models with GEE at the individual and ZCTA levels, respectively, are available in
the Appendix (S1 File). Maps were generated using ArcGIS version 10.1 (Environmental Sys-
tems Research Institute, Redlands, CA) and statistical analyses were performed using Stata ver-
sion 12.1 (StataCorp, College Station, TX).
Results
Among 78,993 adults with 444,212 person-years of follow-up, the median time in care was 7
(Interquartile Range: 4–9) years. The Midwest sample had the smallest percentage of regional
prevalent HIV cases with 3.7% (3,583/97,711); the West had the highest percentage with 7.5%
(12,037/159,523), using CDC data for prevalent HIV cases from 2009 as the denominator (the
last year in which all 12 clinical cohorts contributed data).[49] There were significant differ-
ences between US geographic regions in the percentage of person-time retained for each demo-
graphic and clinical characteristic evaluated (Table 1).
The percentage of individuals successfully retained increased from 2000 to 2010 in each
region: from 73% (5,000/6,875) to 85% (7,189/8,462) in the Northeast, 75% (1,778/2,356) to
87% (1,630/1,880) in the Midwest, 68% (8,451/12,417) to 80% (9,892/12,304) in the South, and
68% (5,147/7,520) to 72% (6,401/8,895) in the West (Fig 1).
In adjusted regression models, there was a trend for improved retention over time (p<0.01)
for all regions. Over the study period, the probability of retention was lower in the West (Risk
Ratio (RR): 0.94; 95% Confidence Interval (CI): 0.92–0.95) and South (RR: 0.94; 95% CI: 0.93–
0.95), and no different in the Midwest (RR: 1.02; 95% CI: 1.00–1.05), compared to the North-
east (p<0.01). Other factors including younger age, male sex, Black race, and IDU and Hetero-
sexual contact as HIV acquisition risk factors were significantly associated with a decreased
likelihood of retention (Fig 2).
We found significant effect modification for racial differences in retention by region, in
which the risk of retention among Black patients was poorer relative to White patients in the
South than in other regions (RR: 0.94; 95% CI: 0.93–0.96, for Black vs. White patients in the
South vs. the Northeast). We also found significant associations of baseline CD4+ count with
retention within the Northeast, South, and West. However, the association in the Northeast
Geographic Variations in Retention in HIV Care in the United States
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Table 1. Percent of person-years successfully retained (with % person-years contributed) in the NA-ACCORD, defined by encounters, stratified by
demographic, clinical, and geographic characteristics, from 2000 through 2010.
Total Northeast Midwest South West
Person-Years (PY) % PY Retained % PY Retained % PY Retained % PY Retained
Factor (% PY ctrbtd.) (% PY ctrbtd.) (% PY ctrbtd.) (% PY ctrbtd.) (% PY ctrbtd.)
Total 7 444,212 (100) 78 (22) 81 (7) 73 (45) 75 (26)
Age (years)*
39 118,626 (27) 69 (24) 72 (24) 63 (28) 62 (27)
40–49 166,389 (37) 77 (38) 81 (37) 73 (36) 70 (39)
50–59 114,784 (26) 83 (28) 84 (27) 80 (26) 76 (24)
60 44,413 (10) 88 (10) 89 (12) 88 (10) 83 (10)
Sex
Male 367,048 (83) 78 (74) 80 (86) 74 (82) 71 (90)
Female 77,164 (17) 77 (26) 83 (14) 69 (18) 67 (10)
Race/Ethnicity
Non-Hisp. White 183,580 (41) 80 (28) 83 (45) 77 (36) 71 (62)
Non-Hisp. Black 194,787 (44) 77 (51) 78 (46) 71 (55) 68 (18)
Hispanic 48,125 (11) 78 (19) 84 (4) 73 (7) 71 (12)
Other/Unk. 17,720 (4) 70 (2) 81 (5) 72 (2) 67 (8)
HIV Risk Factor
MSM 152,691 (34) 79 (28) 83 (30) 73 (28) 69 (52)
IDU 86,301 (19) 76 (26) 76 (18) 72 (20) 69 (14)
Hetero 95,869 (22) 78 (30) 82 (17) 68 (23) 66 (13)
Other/Unk. 109,351 (25) 78 (16) 81 (35) 79 (29) 77 (21)
CD4+ Cell Count (cells/mm3)a
<200 73,559 (17) 81 (16) 85 (15) 74 (18) 76 (15)
200–349 75,340 (17) 84 (18) 87 (15) 79 (17) 74 (17)
350–499 77,588 (17) 85 (17) 89 (16) 81 (17) 74 (19)
500 134,202 (30) 86 (30) 90 (31) 82 (28) 74 (33)
Missing 83,523 (19) 49 (19) 56 (23) 50 (20) 47 (16)
HIV-1 RNA (copies/mL)b
200 copies 178,803 (40) 76 (41) 81 (38) 70 (44) 68 (34)
<200 copies 198,980 (45) 88 (47) 92 (42) 86 (39) 77 (54)
Missing 66,429 (15) 46 (12) 56 (20) 54 (17) 46 (13)
ART Receipt (6 months/year)
<6 months ART 170,251 (38) 59 (37) 62 (37) 55 (41) 53 (35)
6 months ART 273,961 (62) 88 (63) 92 (63) 86 (59) 80 (65)
Percent of person-years retained during the study by encounter (i.e., years “in care” between cohort entry and final encounter) is different by region within
every stratum (χ2 test, p<0.01)
*: age at cohort enrollment
a: at the first measurement in each calendar year during follow-up;
b: at the last measurement in each calendar year during follow-up
Region information missing for residents of Puerto Rico (N = 255), the US Virgin Islands (5), or where state-level residence was missing (N = 12)
Ctrbtd.: contributed; MSM: male sexual contact with men; IDU: injection drug use; Hetero: heterosexual contact; ART: antiretroviral therapy (3 agents
from 2 classes or a triple-NRTI regimen containing abacavir or tenofovir)
doi:10.1371/journal.pone.0146119.t001
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(RR: 1.03 for both 200–349 and for500 vs.<200 cells/μL; p = 0.02 each) was in the opposite
direction of the relationship in the South andWest (higher baseline CD4+ count was associated
with between 3 and 6% decreased probability of retention vs.<200 cells/μL; p0.01 each,
Table A in S1 File). Further, receipt of ART at baseline was associated with between 22 and
30% increased probability of retention within each region (p<0.01 each, Table A in S1 File). In
each of these secondary analyses, the magnitude, direction, and significance of the associations
between age group, sex, race, HIV risk factor, geographic region and retention were similar to
those in the primary analysis (data not shown). Though state-level patterns generally con-
formed to the regional patterns observed (Southern and Western states lagged in observed
and predicted retention probabilities over time), adjusting for state in the full model did not
improve the model fit considerably. (Part F of Fig A in S1 File).
Fig 1. Temporal trends in percentage of individuals successfully clinically retained in the NA-ACCORD by CDC-defined region of the United
States, from 2000–2010, by CDC-defined region of the United States.Diamonds are National HIV/AIDS Strategy/Institute of Medicine retention indicator
percentages (2 visits in a calendar year, >90 days apart). Circles are Predictive Margins for the Probability of Being Retained by IOM indicator using a
Region-by-Time interaction effect (Fully Adjusted Logistic Model with GEE) U.S. Centers for Disease Control and Prevention (CDC)-defined Regions:
Northeast: CT, ME, MA, NH, NJ, NY, PA, RI, VT;Midwest: IL, IN, IA, KS, MI, MN, MO, NE, ND, OH, SD, WI; South: AL, AR, DE, DC, FL, GA, KY, LA, MD,
MS, NC, OK, SC, TN, TX, VA, WV;West: AK, AZ, CA, CO, HI, ID, MT, NV, NM, OR, UT, WA, WY.
doi:10.1371/journal.pone.0146119.g001
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In models at the ZCTA-level, only an increase in median age (Odds Ratio (OR): 1.10 per
year; 95% CI: 1.09–1.11) and a decrease in the census-based proportion of a ZCTA that were of
Black race (OR: 0.36 per percentage difference increase from the mean proportion; 95% CI:
0.15–0.87) were significantly associated with improved retention (Table 2).
Discussion
We found that among PLWHA successfully linked to and enrolled in care, the percentage of
patients who were retained in care improved over time for all regions, with 72–87% retained in
care in 2010. Despite this finding, the South andWest exhibited lower retention levels over
time compared to the Northeast. The results regarding the South are of particular concern in
that they are troublingly consistent with surveillance and prior studies showing worse HIV out-
comes, and significant sex and race disparities in these outcomes, compared to the rest of the
U.S.[17,19–22] In the South, with its history of poorer educational performance, poorer access
to healthcare than much of the rest of the country, and regressive policies with respect to
racial/ethnic and sexual minorities, the lag in improved quality of care outcomes could be the
Fig 2. Risk Ratio estimates and 95%Confidence Intervals for factors associated with retention.Results frommodified Poisson regression model using
a Generalized Estimating Equation and adjusting for total time in care.
doi:10.1371/journal.pone.0146119.g002
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product of several forces.[17,18,21] A geographically dispersed epidemic with residents of
more rural areas who have longer commutes to clinic locations in primarily urban centers
could affect the observed outcomes. Social stressors and structural factors that may limit the
ability of individuals to access care (e.g., poverty, housing instability, discrimination, etc.) may
also play an outsize role in the observed disparity of care between the South and Northeast, as
noted in prior work.[21] However, further research will be required to explore the role of these
factors in clinical care in this patient population.
Despite regional disparities, however, the improvement in retention adds further evidence
to earlier research that showed increasing percentages of large linked and clinically-engaged
populations being retained over long periods of follow-up in the U.S.[39,45,48] Notably, this
upward trend persisted, even after adjusting for demographic, geographic, and HIV risk factor
differences, and after accounting for differential contributions of time at risk for leaving care.
This may have been due to increased attention to clinical retention during the study period or
to increasing numbers of individuals placed on ART,[18,45] requiring increased engagement
between patient and providers. Examining retention patterns by CD4+ count at cohort entry, a
marker of delayed diagnosis or linkage to care, the South and West again exhibited decreased
retention compared to the Northeast, though by similar magnitudes regardless of CD4+ stra-
tum. This indicates that CD4+ count at entry to care did not significantly influence differences
in retention over time between patients in the Northeast, South, and West, even though base-
line CD4+ count differed between patients subsequently retained and not retained across the
US.[38,39] Though this appears to bode well for efforts to improve retention among all pre-
senters for HIV care, it remains a powerful indication that even among patients linked to care
early in infection, there may remain structural factors that are region-specific which may domi-
nate patients’ subsequent experiences of care.
Regarding ART use at cohort entry, an indicator of access to care, a fairly strong positive
association between ART use and retention regardless of region may indicate the power of
Table 2. Estimated 95% Odds Ratios CIs for retention from ZCTA-level regression models.
Full Model Model 2 Model 3 Model 4
QIC (Adjusted) 8724.7 8724.7 8722.8 8722.3
Median Age (Yrs.) 1.09 1.10 1.11 1.09 1.10 1.11 1.09 1.10 1.11 1.09 1.10 1.11
Sample Proportion Female Sex 0.74 2.39 7.72 0.75 2.40 7.72 0.75 2.39 7.72
Sample Proportion Black Race 0.39 0.65 1.09 0.39 0.65 1.09 0.39 0.65 1.09 0.40 0.65 1.09
Sample Proportion IDU Risk 0.64 1.03 1.68 0.64 1.03 1.68 0.64 1.03 1.68 0.67 1.08 1.75
Census Proportion Female Sex 0.00 10.80 48302.1
Census Proportion Black Race 0.15 0.36 0.87 0.16 0.38 0.90 0.17 0.37 0.82 0.17 0.37 0.83
Census Proportion Rural Area 0.67 1.01 1.53 0.66 0.97 1.46 0.66 0.97 1.43 0.67 0.98 1.44
Census Proportion Living Below Poverty Line 0.14 0.87 5.38 0.16 0.94 5.70
Region
Northeast Reference Reference Reference Reference
Midwest 0.75 0.96 1.26 0.74 0.95 1.24 0.74 0.95 1.24 0.74 0.95 1.24
South 0.88 1.14 1.48 0.87 1.12 1.46 0.87 1.12 1.45 0.87 1.12 1.45
West 0.68 0.92 1.25 0.68 0.89 1.18 0.68 0.89 1.17 0.68 0.89 1.17
Bold point estimates are statistically significant (p<0.05)
QIC: the Quasi-likelihood Information Criterion of Pan (a measure of model fit, compared with an independent working correlation structure)
All logistic regression models used GEE with an unstructured working correlation structure, and all sample and census proportions were mean-centered
Increasing total time in care was also significantly associated with improved retention (OR: 1.00, 95% CI: 1.00–1.01, for all models)
doi:10.1371/journal.pone.0146119.t002
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personal experience in engaging with healthcare services. This may include improved self-effi-
cacy among patients and motivation to maintain contact with care providers once personally
invested in their own medical care through ART use. However, it may also be the case that cli-
nician decisions on initiating or continuing therapy favor patients more likely to improve their
retention in care or those who have demonstrated stability in their clinic visit patterns (e.g.,
delaying ART initiation in IDU patients if they are actively using).[60] This does contradict
reports of widespread clinician willingness to initiate therapy early in care among high risk
patients, though in the largest such survey of clinician attitudes, the surveys were conducted
only in New York andWashington, D.C.[61]
Many of the same groups that have been previously identified with suboptimal retention in
care and inferior HIV outcomes in general, again emerged in this analysis. These groups
include: younger individuals, Black patients, and those with IDU as HIV risk factor.[29,32,62–
64] Even though the unadjusted retention rates among these groups approaches the NHAS
goal of 80% (among Ryan White clients), there is room for improvement when compared to
other HIV-infected sub-populations. Given those deficits, and the fact that risk networks,
culture, and socioeconomics may differ across regions, states, and more granular geographic
levels, the identification of locales that may benefit most from interventions to improve health-
care quality, access, and retention remains as important as ever. Clinicians and public health
practitioners should note that though vulnerable and high burden groups identified again here
may be obvious targets for interventions to improve access to and retention in care, their defi-
cits may differ by region, and a “one size fits all” approach at the national (and perhaps even
the regional) level may not be warranted. It may even be the case that simply expanding the use
of ART at entry to care may improve patient engagement and retention. Further analysis will
be required to isolate the potential effects of individual clinical decision-making before con-
cluding that the observed relationship between ART use and retention is not due to confound-
ing, though.
In this analysis, the regions analyzed were quite large, and economic, social, cultural, and
political factors may vary widely even within regions (e.g., the most and least populous US
states, California and Wyoming, respectively, are in the same geographic region- the West).
Because within-region and between-region differences may play significant roles influencing
differences in retention and other HIV outcomes, the monitoring of geographic trends in HIV
clinical care, including all stages of the continuum, is an important activity to provide evidence
for targeted outreach beyond a simple risk-group basis.
The additional analysis of ZCTA-level data, though providing a different lens through
which to view demographic and HIV risk differences in retention in the US, add value in the
additional layers of evidence they may provide to policy makers, particularly if individual-level
data is unavailable.[65–67] Population-level differences in contextual factors such as poverty,
crime, and housing instability may also be a desirable focus for policy when considering aggre-
gate characteristics separately from individual characteristics related to care at a more granular
level than the state or region. In this case, the differences observed are unlikely to stem from
confounding by measured factors since the ZCTA-level analyses were adjusted using demo-
graphic and HIV risk characteristics, though they may be confounded by characteristics of the
area of aggregation that were unavailable (such as public insurance income thresholds). Despite
the limits in this context, these ZCTA-level analyses offer valuable insight into population-level
processes such as persistent disparities in retention associated with regional age structure and
racial composition that may be occurring in the care continuum at divisions smaller than the
state level.
Scrutinizing outcomes at varying levels of geographic resolution is useful (and perhaps nec-
essary) for detecting patterns that may otherwise be obscured.[68] Noting retention patterns
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across ZCTA, state, and region levels, our work found fairly consistent trends, though the qual-
ity of inferences may not necessarily reflect the level at which public health actions are likely to
be taken or at which effects may be most powerfully felt (Figs 3, 4 and 5). In the region-level
map, the inter-regional disparities in retention are clearer, while increasing levels of magnifica-
tion present a more complicated picture with the patterns less discernable. However, when
describing disparate HIV quality of care outcomes, it may be particularly powerful to depict
trends across areas that have been noted to have somewhat distinct cultures, political struc-
tures, and epidemic profiles, as denoted by the disaggregation of data across these very same
regions in national HIV surveillance reports.[49] The assessment and mapping of these out-
comes at various levels, which is itself unusual, provides a compelling depiction of these HIV
outcomes in a more easily accessible and readable format for both scientific and lay audiences.
Further analysis incorporating smaller geographic divisions with richer individual- and
population-level data (e.g., Medicaid status at the individual-level) will be required to better
understand how geographic factors, and the social-structural characteristics they may be prox-
ies of, impact retention in clinical care and HIV outcomes.
There were limitations in this analysis. First, medical insurance status and economic secu-
rity are important factors influencing access to and retention in clinical care and which we did
Fig 3. Region-level map of observed clinical retention status within the study sample in 2009 (N = 47,247), the final year in which all 12 clinical
cohorts contributed data.
doi:10.1371/journal.pone.0146119.g003
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not have access to. We did, however, use census-derived proxies for socioeconomic data such
as the proportion of the ZCTA that was rural (indicating longer travel to receive care) and the
proportion of the ZCTA living below the Federal poverty line (indicating economic and insur-
ance resources available to patients). Second, the group under observation was successfully
linked to care and engaged at cohort enrollment, and therefore may not represent populations
of greatest concern in the early stages of the continuum of care.
Using data from a large North American collaborative HIV cohort, our analysis demon-
strated a persistent upward trend in retention in care across the U.S., but one that was differen-
tial in its extent by region. These differences correspond with observations of regional
differences in other HIV outcomes and highlight the utility of geographic data and analyses in
monitoring progress in the continuum of care on both a national and a local basis. Though pol-
icy prescriptions and public health actions such as expanded testing and prevention services or
improved linkage and treatment programs may help stem the tide of the epidemic, knowing
that they may be more urgently needed in the South or the West, as opposed to the Northeast,
is surely a critical piece of information.[69]
Fig 4. State-level map of observed clinical retention status within the study sample in 2009 (N = 47,247), the final year in which all 12 clinical
cohorts contributed data.
doi:10.1371/journal.pone.0146119.g004
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